Neurocrine Biosciences | Ventes



Sales Changement Date
AbbVie USD 15.1B 642M 2024-12
Acadia Pharmaceuticals USD 259.6M 9.2M 2024-12
Agios Pharmaceuticals USD 10.73M 1.77M 2024-12
ALKERMES USD 430M 51.9M 2024-12
Alnylam Pharmaceuticals USD 593.17M 92.25M 2024-12
Amgen USD 9.09B 583M 2024-12
Biogen USD 2.45B 11.1M 2024-12
BioMarin Pharmaceutical USD 747.31M 1.57M 2024-12
Cytokinetics USD 16.93M 16.46M 2024-12
Dynavax Technologies USD 72.03M 8.6M 2024-12
Exelixis USD 566.76M 27.21M 2024-12
Gilead Sciences USD 7.57B 24M 2024-12
Halozyme Therapeutics USD 298.01M 7.92M 2024-12
Incyte USD 1.18B 40.83M 2024-12
Intra Cellular Therapies USD 199.22M 23.85M 2024-12
Ionis Pharmaceuticals USD 226.58M 92.76M 2024-12
Neurocrine Biosciences USD 627.7M 5.6M 2024-12
Pfizer USD 17.76B 61M 2024-12
Prothena USD 2.12M 1.15M 2024-12
Regeneron Pharmaceuticals USD 3.79B 70M 2024-12
Repligen USD 168M 13M 2024-12
Sarepta Therapeutics USD 658.41M 191.24M 2024-12
Teva Pharmaceutical Industries USD 15.33B 11B 2024-12
Ultragenyx Pharmaceutical USD 164.88M 25.38M 2024-12
Vertex Pharmaceuticals USD 2.91B 140.1M 2024-12



Neurocrine Biosciences Ventes - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.